Lundbeck forges CNS pact with Zenobia, Vernalis

Denmark's Lundbeck has forged development pacts with Vernalis as well as Zenobia Therapeutics on an brain enzyme inhibition program designed to target CNS (central nervous system) ailments such as Parkinson's. Zenobia's technology will be used to crystallize and visualize the enzyme. "These collaborations are important supplements to Lundbeck's commitment to provide new, innovative medicines in the CNS field, in areas with high unmet needs," Lundbeck's Peter Hongaard Andersen, executive vice-president, research management, said in a statement. "It is this type of drug we expect will be in demand in the future." Report

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.

A Cedars-Sinai team used stem cells to uncover a key mechanism of young onset Parkinson's, as well as a potential remedy—an existing skin treatment.